Sanofi's 650 million acquisition of protein science

Source: does ihealth 2017-07-12 mean Sanofi is in a hurry to get the potential? Sanofi announced on July 11 that it would take protein sciences, a private vaccine biotechnology company based in Connecticut, into its pocket But in contrast to other such transactions, Sanofi will pay up to six times the previous payment in a lump sum compared to the later milestone payment According to the terms of the agreement, Sanofi will pay US $650 million in advance, but only US $100 million after reaching some milestones This surprised analysts, and also showed that the French pharmaceutical company and vaccine manufacturer were determined to acquire protein science Why is protein science so bullish? This may be because the U.S private vaccine manufacturer just got approval from the U.S Food and Drug Administration (FDA) in October last year to launch the flublock four price influenza vaccine (QIV) Flublock is the only FDA approved influenza vaccine based on recombinant protein The vaccine market has changed dramatically, and the traditional egg based production method is being replaced by gene recombination The reason is that the traditional production cycle is longer, the cost is higher, and the requirements are higher However, the influenza vaccine market needs more influenza virus strains in the current season to produce batch vaccines for the market in a short time, so new production methods are in the ascendant "The acquisition of protein science will enable us to expand the influenza vaccine portfolio and increase non egg vaccines "Said David Loew, executive vice president and head of Sanofi Pasteur At the same time, as one of the world's five largest vaccine manufacturers, Sanofi's global channel will bring considerable prospects to flublock, which is the place of value for protein science "Protein science is actively looking for business opportunities, especially in the United States As part of Sanofi Pasteur, we expect that flublok influenza vaccine will benefit from Sanofi Pasteur's expertise in the field of influenza vaccine " Manon Cox, President and CEO of protein science, said The deal will be completed in the third quarter of 2017, subject to the approval of regular regulators.